---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008063"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:12:34.496118+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025

## Summary
- Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.
- In April 2024 received $30M upfront + $13.5M equity from Gilead; up to $592.5M in potential milestones.
- Plan to initiate Phase 2 trial for XTX101 (anti-CTLA-4) in MSS CRC in Q3 2024; data in Q4 2024.
- Discontinued XTX202 monotherapy; exploring combo development opportunities.
- Cash runway expected into Q2 2025, including $44.6M in April gross proceeds from Gilead and private placements.

## SEC filing metadata
- accession: 0001558370-24-008063
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/xlo-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008063
- JSON: https://secwatch.observer/filing/0001558370-24-008063.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008063.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for quarter ended March 31, 2024.
  - Period: quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.